期刊文献+

以树突状细胞为基础的血液恶性肿瘤免疫治疗研究进展

下载PDF
导出
摘要 机体的免疫应答,是抗原递呈细胞(antigenpresenting cell,APC)首先捕获抗原,经过加工处理后将抗原信号传递给T细胞和B细胞。引发一系列的免疫反应。树突状细胞(dentritic cell,DC)是已知的功能最强的专职APC,能够摄取抗原,还可以摄取和转运抗原的特殊膜受体,同时能高效摄取低浓度抗原,是促进T、B淋巴细胞增殖的高效刺激因子。而且,少量的抗原与DC作用足以激活T细胞。因此,DC被认为是联系天然防御功能和获得性免疫的关键。
作者 李慧 谭晓华
出处 《实用医学杂志》 CAS 2007年第22期3628-3629,共2页 The Journal of Practical Medicine
基金 国家自然科学基金资助项目(编号:30271185 30371627) 北京市自然科学基金资助项目(编号:7042062)
  • 相关文献

参考文献10

  • 1罗姝,陈三军(审校).树突状细胞在多发性骨髓瘤免疫治疗中的应用进展[J].国际免疫学杂志,2006,29(6):399-403. 被引量:1
  • 2朱雄鹏,陈志哲.基因修饰树突状细胞诱导抗血液肿瘤效应的研究进展[J].国际输血及血液学杂志,2006,29(2):163-166. 被引量:1
  • 3Liu A, Takahashi M, Narita M, et al. Generation of functional and mature dendritic cells from cord blood bone marrow CD34^+ cell by tow step culture combined with calcium innophore treatment [J]. K Immunol Med, 2002, 216(6) :49 63.
  • 4Li Q, Ozer H, Lindner I, et al. Protein Kinase C block inhibits differentiation of myeloid blasts into dendritic cells by calcium ionophore A23187 [J]. Int J Hematol, 2005,81 (2) : 131-137.
  • 5Takahashi T, Tanaka Y, Nieda M, et al. Dendritic cell vaccination for patients with chronic myelogeous leukmia [J]. Leuk Res, 2003,27 (9) : 795-802.
  • 6Klammer M, Waterfall M, Samuel K, et al. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential vaccine for acute myeloid leukaemia [J]. Br J Heamatol, 2005,129 (3) : 340-349.
  • 7Westers T M, Houtenbos I, Snoijs N C, et al. Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity [J]. Leukemia, 2005, 19(7) : 1270-1272.
  • 8陈健君,石庆之,余莉,陈三军,华建媛.阳离子脂质体包裹急性髓系白血病可溶性蛋白抗原诱导细胞毒性T淋巴细胞作用[J].中华血液学杂志,2005,26(1):56-57. 被引量:7
  • 9Qian J, Wang S, Yang J, et al. Targeting heat shock proteins for immunotherapy in multiple myeloma:generation of myelomaspecific CTLs using dendritic cells pulsed with tumor-derived gp96 [J]. Clin Cancer Res, 2005,11 (24 Pt 1 ) : 8808-8815.
  • 10Elisabeth H S, Willy M H, Edith D M, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as apotential target for immunotherapy of cancer [J]. Blood, 2006,107 ( 12 ) : 4954-4960.

二级参考文献48

  • 1Brossart P,Wirths S,Brugger W, et al. Dendritic cells in cancer vaceines. Exp Hematol,2001,29(11 ):1247-1255.
  • 2Trombetta ES, Ebersold M, Garrett W, et al. Activation of lysosomal function during dendritic cell maturation. Science. 2003 299(5611):1400-1403.
  • 3Lanzavecchia A , Sallusto F. Regulation of T cell immunity by dendritic cells. Cell ,2001,106 (3) : 263-266.
  • 4Dannull J, Cerny T, Ackermann DK,et al. Current Status of Dendritic Cell-Based Tumor Vaccination. Onkologie,2000,23(6) :544-551.
  • 5Wu MH, Smith SL, Dolan ME. High efficiency electroporation of human umbilical cord blood CD34 + haematopoietic precursor cells. Stem Cells,2001,19(6) :492-499.
  • 6Pisarev V, Yu B,Salup R,et al. Full-length dominant-negative surviving for eaneer immunotherapy. Clin Caneer Res, 2003, 9(17) : 6523-6533.
  • 7Nikitina EY, Chada S, Muro-Cacho C, et al. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther, 2002, 9(5) :345-352.
  • 8Okada N, Masunaga Y, Okada Y. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther, 2003,10(5): 421-431.
  • 9Herrera OB, Brett S, Lechler RI. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class Ⅰ and class Ⅱ molecules-potential benefits in vaccine design.Clinical Cancer Research, 2002,21 (3-4) : 231-242.
  • 10Wang X,Uto T,Sato K ,et al. Potent activation of antigen-specific T cells by antigen-loaded nanospheres. Immunol Lett, 2005,98(1):123-130.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部